Michele Frances Alston, | |
Unit 33100 Box Landstuhl, Apo, AE 09180-3100 | |
(314) 590-7114 | |
Not Available |
Full Name | Michele Frances Alston |
---|---|
Gender | Female |
Speciality | Physical Medicine & Rehabilitation |
Location | Unit 33100 Box Landstuhl, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427477850 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | 53300 (Tennessee) | Secondary |
208100000X | Physical Medicine & Rehabilitation | 53300 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Michele Frances Alston, Cmr 402 Box 245, Apo, AE 09180-0003 Ph: () - | Michele Frances Alston, Unit 33100 Box Landstuhl, Apo, AE 09180-3100 Ph: (314) 590-7114 |
News Archive
VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.
If you work from home part of the week as a teleworker, does it help reduce work exhaustion caused by juggling work and family commitments? The answer may depend on the level of conflict you have between work and home and your ability to recharge your batteries adequately, according to Professor Timothy Golden, from the Rensselaer Polytechnic Institute in Troy, NY.
NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize ZolpimistĀ® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.
The GE Foundation - the philanthropic organization of GE - announced today the award of $500,000 to two Erie-based community health centers in an effort to help increase access to quality healthcare across the United States.
› Verified 3 days ago